Yu-Ning Wong, MD, MSCE
- Request Appointment
- Clinical Locations
- Education, Training & Credentials
- Patient Stories
- Research Profile
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Program Director, Genitourinary Medical Oncology
Associate Professor, Department of Hematology/Oncology
The introduction of new treatments for patients with localized and advanced cancer has made this an exciting time to be a medical oncologist. After I finished my training in 2005, I decided to stay at Fox Chase to pursue my research in how cancer affects both individuals and populations. Within the Genitourinary Malignancy Division, I work with other researchers to develop new treatments for prostate, urothelial, kidney and testicular cancers. I am an active clinical investigator and am able to offer patients both standard therapy as well as novel therapies through well-conducted clinical trials. As an investigator involved in recent trials that ultimately led to approval of new therapies for kidney and prostate cancer, I truly believe that clinical trials improve cancer care for current and future patients.
I enjoy taking care of patients across the age spectrum, and have been fortunate to get to know many of my patients and their families very well. I believe that it is my responsibility to help patients and families arrive at a treatment decision that improves their outcomes and reflects their preferences and beliefs.
I enjoy working my colleagues in the Genitourinary Malignancy Division at Fox Chase. All of the clinicians (Physicians, Advanced Practice Clinicians, Nurses and Medical Assistants) work closely together to ensure that care is as coordinated as possible.
Working at Fox Chase has provided me the opportunity to treat patients as well as pursue cancer research. Although I see primarily patients with genitourinary malignancies, the academic environment allows me to stay aware of new advances in other disease sites. I often use this knowledge in caring for my own patients.
- Fellow, Hematology and Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA
- Fellow, Fox Chase Cancer Center and Temple University Hospital, Philadelphia, PA
- Fellow, Clinical Epidemiology, University of Pennsylvania, Philadelphia, PA
- Resident, Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
- MS, Clinical Epidemiology, University of Pennsylvania, Philadelphia, PA
- Robert Wood Johnson Medical School, University of Medicine and Dentistry, New Brunswick, NJ
- Internal Medicine, Oncology
- American Society of Clinical Oncology
- Eastern Cooperative Oncology Group
In August 2012, at the age of 61, just two months after he retired, Chuck Leonard was diagnosed with stage four kidney cancer that had metastasized to his lungs. His world came crashing down around him. “My wife and I were devastated,” admits Chuck. “The cancer totally occupied our daily thoughts. Neither of us could sleep. We could barely function.”
In 2006, at age 51, David Juall was a healthy, active attorney, and a pilot, who enjoyed traveling and outdoor fun. During a court proceeding in Bucks County, he had a medical emergency and was taken to a local community hospital. It turned out he needed an emergency appendectomy. As part of his treatment, CT scans were ordered. One of the doctors discovered a suspicious spot on one of his kidneys.
Understanding body changes and symptoms can sometimes be challenging. At age 55 in March, 2009, Jesus “Jess” Calderón was experiencing muscle spasms and lower back pain. At first he thought the pain may be caused by kidney stones. His devoted wife, Inez, suggested he see his family doctor for a full evaluation. Diagnostic scans revealed a mass the size of a cantaloupe on Jess’ left kidney. The malignant neoplasm was treated by a nephrectomy to remove his left kidney in October 2009 at his local hospital.
Working in retail takes a person with an outgoing personality and a commitment to customer service. “I really like the pace of working in the store,” says Andrew Steinmetz, 23, who is a manager at a business supply store in Philadelphia. “I like helping customers and meeting new people.” Andrew’s upbeat and positive attitude is evident as he shares the story of his battle of testicular cancer.
- Genitourinary malignancies
Financial Concerns Among Cancer Patients About Participation In Clinical Trials Wong,Yu-Ning,, Schlucter,Mark,D, Albrecht,Terrance,L, Benson,Al,B, Buzaglo,Joanne,, et al. Journal of Clinical Oncology. PubMed
Randomized Trial of a Web-based Intervention to Address Barriers to Clinical Trials Meropol,Neal,J, Wong,Yu-Ning,, Albrecht,Terrance,L, Manne,Sharon,, Miller,Suzanne,M, et al. Journal of Clinical Oncology. PubMed
Adjuvant Chemotherapy Use and Healthcare Costs after the Introduction of Genomic Testing in Breast Cancer Epstein,Andrew,J, Wong,Yu-Ning,, Mitra,Nandita,, Vachani,Anil,, Hin,Sakhena,, et al. Journal of Clinical Oncology. PubMed
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5. PubMed PMID: 26244877, PMCID:PMC4562797 PubMed
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, et al. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Aug 1. doi:pii: S0302-2838(15)00613-2. 10.1016/j.eururo.2015.07.009. [Epub ahead of print] PubMed PMID: 26238431 PubMed
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20;32(18):1895-901. doi: 10.1200/JCO.2013.53.2465. Epub 2014 May 12. PubMed PMID: 24821881, PMCID: PMC4050203 PubMed
Bilusic M, Wong YN. Anti-angiogenesis in prostate cancer: knocked down but not out. Asian J Androl. 2014 May-Jun;16(3):372-7. doi: 10.4103/1008-682X.125903. Review. PubMed PMID: 24759579, PMCID: PMC4023362 PubMed
Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012 Oct 1;30(28):3545-51. Epub 2012 Aug 27. Erratum in: J Clin Oncol. 2013 Oct 1;31(28):3612. PubMed PMID: 22927525, PMCID: PMC3454772 PubMed
Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol. 2009 Jan 1;27(1):100-5. doi: 10.1200/JCO.2007.14.2042. Epub 2008 Dec 1. PubMed PMID: 19047295, PMCID: PMC2645095 PubMed
Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F, Montagnet C, Armstrong K. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006 Dec 13;296(22):2683-93. Erratum in: JAMA. 2007 Jan 3;297(1):42. PubMed PMID: 17164454 PubMed